NEBIVOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H25F2NO4
Molecular Weight	405.4358
Optical Activity	( + / - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1C[C@]([H])([C@@]([H])(CNC[C@]([H])([C@]2([H])CCc3cc(ccc3O2)F)O)O)Oc4ccc(cc14)F

InChI

InChIKey=KOHIRBRYDXPAMZ-YHBROIRLSA-N

InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18-,21-,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H25F2NO4
Molecular Weight	405.4358
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18485134 | https://www.ncbi.nlm.nih.gov/pubmed/9825177 | https://www.ncbi.nlm.nih.gov/pubmed/21283024 | https://www.ncbi.nlm.nih.gov/pubmed/1681809 | https://www.ncbi.nlm.nih.gov/pubmed/1357130https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | http://www.bystolic.com/

Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. Marketed under the brand name BYSTOLIC, Nebivolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 153 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2455841 \| https://www.ncbi.nlm.nih.gov/pubmed/2462161 \| https://www.allergan.com/assets/pdf/bystolic_pi \| https://www.ncbi.nlm.nih.gov/pubmed/11309254	Antagonist 2575		0.7 nM [Ki]
Beta-1 adrenergic receptor 153 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21283024 \| https://www.ncbi.nlm.nih.gov/pubmed/1681809	Antagonist 2575		0.35 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 515 Sources: https://www.allergan.com/assets/pdf/bystolic_pi https://www.drugs.com/pro/nebivolol.html https://www.ncbi.nlm.nih.gov/pubmed/19393838	Primary		Approved 8043	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 1.19784958E12
Hypertension 515 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7596131 https://www.ncbi.nlm.nih.gov/pubmed/7692155 https://www.ncbi.nlm.nih.gov/pubmed/18485134 https://www.ncbi.nlm.nih.gov/pubmed/1357130	Primary		Approved 8043	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 1.1977632E12

C_max

Value	Dose	Co-administered	Analyte	Population
1.48 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7.76 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unknown		NEBIVOLOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	Disc. AE: Hyperhidrosis, Pallor... AEs leading to discontinuation/dose reduction: Hyperhidrosis Pallor Depressed level of consciousness Hypokinesia Hypotension Sinus bradycardia Hypoglycemia Hypokalemia Respiratory failure Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (0.4%) Nausea (0.2%) Bradycardia (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Co-administed with:: valsartan, oral(80 mg, qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Depressed level of consciousness	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hyperhidrosis	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypoglycemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypokalemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypokinesia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypotension	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Pallor	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Respiratory failure	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Sinus bradycardia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Vomiting	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Bradycardia	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Nausea	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Headache	0.4% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Disorder fetal	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Co-administed with:: valsartan, oral(80 mg, qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	inhibitor 1604	substrate 1118 inhibitor 1702

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2A6 627 CYP2B6 717 CYP2C8 818 CYP2C19 1325 CYP3A4/5 241

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2A6 659	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2B6 884	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C8 865	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C9 1648	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP3A4/5 293	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 28, 50, 55	minor
CYP2D6 1118	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0	yes		yes (co-administration study) Comment: from product label: fluoxetine coadministration led to increased AUC by 8% and Cmax by 3-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
AChemBlock	10241
AK Scientific	M753
Aronis	BBC/719
BOC Sciences	118457-15-1
IBScreen	BB_SC-12513
IBScreen	Bio-0068
Lab Network	LN01346236
MolPort	MolPort-003-849-342
MolPort	MolPort-023-276-830
ShangHai Biochempartner	BCP21038
Tocris	3517
Toronto Research Chemicals	N387896
Vitas-M Laboratory	STK637549
ZINC	ZINC000003951631	http://zinc15.docking.org/substances/ZINC000003951631
eMolecules	29703203
eMolecules	300435536
eMolecules	30387256
mcule	MCULE-7932280679

PubMed

Title	Date	PubMed
Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.	1993 Aug	7692155
Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.	1998 Sep	9825177
[Effect of nebivolol on the level of constitutional, inducible, and total NO-synthase in serum of patients with type II diabetes mellitus].	2002	12669563
[Effect of enape combined with nebilet in hypertension].	2002	12587324
[Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].	2002	12577837
[Assessment of efficacy and safety of nebivolol in patients with stable effort angina].	2002	12494203
[Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension].	2002	12494141
[Experience of the use of nebivolol in the treatment of hypertension in postmenopausal women].	2002	12494089
[Effect of nebivolol on dynamics of microalbuminuria, renal blood flow and 24-hour blood pressure profile in patients with hypertension].	2002	12494075
[Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].	2002	12494053
[Assessment of safety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis].	2002	12494034
[Antihypertensive efficacy and tolerability of nebivolol].	2002	12494015
Gateways to clinical trials.	2002 Dec	12616965
No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.	2002 Dec	12512696
[Beta blocker enhances NO liberation in the endothelium. Vascular tone long-term improvement].	2002 Dec 5	12577747
[Cardiac protection by beta-1 selective beta blocker. Still better in the 3rd generation?].	2002 Jul 11	12198891
[Despite antihypertensive treatment with beta-blocker patients remain incapacitated].	2002 May 2	12422716
Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP.	2002 Sep	12223177
Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms.	2002 Sep	12223176
Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.	2002 Sep	12195121
Focus on small artery stiffness.	2002 Sep	12195105
[Nebivolol effects on platelet aggregation and anticoagulation system].	2003	14603912
[Dynamics of a 24-h profile of arterial pressure and function of the vascular endothelium in nebivolol treatment of hypertensive patients].	2003	14520947
[Effect of nebivolol on the state of pituitary-gonadal system and lipid peroxidation in young and middle aged men with hypertension].	2003	12891274
[Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes].	2003	12891271
[Use of nebivolol in patients with mild and moderate hypertension].	2003	12718224
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.	2003 Apr	12658024
Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.	2003 Apr 1	12692005
Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.	2003 Aug	12883327
Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.	2003 Aug 1	12888152
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.	2003 Dec	14761075
[Beta blocker improves the endothelial function. Gas-forming blood vessel protection].	2003 Dec 18	14974334
Effect of forced titration of nebivolol on response rate in obese hypertensive patients.	2003 Jan	12517695
[Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].	2003 Jan 15	12540987
Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.	2003 Jan 26	12535855
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.	2003 Jun	12808486
A comparison of the beta1-selectivity of three beta1-selective beta-blockers.	2003 Jun	12795776
Different effect of antihypertensive drugs on conduit artery endothelial function.	2003 Jun	12719441
Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.	2003 May	12800985
Effects of nebivolol on ischemia-induced metabolic changes in dog hearts.	2003 May	12717108
Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation.	2003 Nov 19	14642697
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.	2003 Oct	14607201
Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats.	2003 Sep	12960679
[Endothelial dysfunction and metabolic effects of nitric oxide in human].	2003 Sep-Oct	14611088
[Nebivolol in the treatment of ischemic heart disease patients with chronic heart failure].	2004	15029131
The shift in the "paradigm" of the pharmacology of hypertension.	2004	14965315
[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].	2004 Apr 8	15054690
Antioxidant activity of nebivolol in the rat aorta.	2004 Jan	14668581
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD.	2004 Mar-Apr	15031571
Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.	2008 Summer	18485134

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 30 patients (mean age 48 years) were randomly allocated to double-blind treatment with either DL-nebivolol 5 mg or D-nebivolol 2.5 mg once daily for 4 weeks.

Route of Administration: Oral

In Vitro Use Guide

Nebivolol and d-nebivolol (SRRR) inhibited noradrenaline-induced cAMP accumulation with IC50 values of 22 and 15 nM, respectively in rat living cardiac cells.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 09:33:10 UTC 2021` Edited by `admin` on `Sat Jun 26 09:33:10 UTC 2021`
Record UNII	030Y90569U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEBIVOLOL

Official Name

English

NEBIVOLOL [VANDF]

Common Name

English

NEBIVOLOL COMPONENT OF BYVALSON

Common Name

English

NEBIVOLOL [INN]

Common Name

English

NEBIVOLOL [MI]

Common Name

English

NEBIVOLOL [MART.]

Common Name

English

NEBIVOLOL [USAN]

Common Name

English

R65,824

Code

English

NARBIVOLOL

Common Name

English

BYVALSON COMPONENT OF NEBIVOLOL

Common Name

English

R-65824

Code

English

2H-1-BENZOPYRAN-2-METHANOL, .ALPHA.,.ALPHA.'-(IMINOBIS(METHYLENE))BIS(6-FLUORO-3,4-DIHYDRO-, (.ALPHA.R,.ALPHA.'R,2R,2'S)-REL-

Common Name

English

.ALPHA.,.ALPHA.'-(IMINODIMETHYLENE)BIS(6-FLUORO-2-CHROMANMETHANOL)

Systematic Name

English

NEBIVOLOL [WHO-DD]

Common Name

English

Classification Tree Code System Code

LIVERTOX

672